HeartMate 3 患者获得性血管性血友病因子缺乏减轻
该回顾性研究比较了70例植入HeartMate 3(HM 3,n=35)或HeartWare(HVAD,n=35)左心室辅助装置患者的血管性血友病因子(vWF)多聚体结构。两组获得性血管性血友病综合征(AvWS)发生率分别为97.1%和100%,但HM 3组高分子量多聚体(HMWM)比例更高、vWF活性更高,提示HM 3对vWF多聚体结构的破坏较轻。
要点
- HM 3组AvWS发生率为97.1%,HVAD组为100%。
- HM 3组HMWM比例高于HVAD组(P<0.01)。
- HM 3组vWF活性高于HVAD组(153.7±54.4% vs 126.3±39.7%,P=0.02)。
核心结论
- 植入HM 3的患者在装置支持期间HMWM更完整且vWF活性更高,可能减轻AvWS表现并降低出血并发症率。
研究设计与样本
- 回顾性研究,共纳入70例植入HM 3(n=35)或HVAD(n=35)的患者,采用光密度法量化vWF多聚体。
主要发现
- HM 3组AvWS发生率为97.1%,HVAD组为100%。
- 与正常混合血浆相比,HM 3组HMWM降低(40.7±8.2% vs 26.7±7.5%,P<0.01),低分子量多聚体升高(31.3±11.8% vs 42.7±9.8%,P<0.01)。
- HVAD组中间分子量多聚体升高(28.0±5.0% vs 38.4±7.7%,P<0.01),HMWM降低至23.0±11.0%(P<0.01)。
- 两种装置间vWF多聚体结构存在差异:HMWM P<0.01,中间分子量多聚体P=0.05,低分子量多聚体P=0.03。
- HM 3组vWF活性为153.7±54.4%,高于HVAD组的126.3±39.7%(P=0.02)。
临床怎么用
- 对于植入左心室辅助装置的患者,HM 3可能较HVAD更有利于保留vWF高分子量多聚体结构和活性,或有助于降低AvWS相关出血风险。
局限性
- 回顾性研究设计,样本量有限(共70例),结论需进一步前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The acquired von Willebrand syndrome (AvWS), which is associated with left ventricular assist device support, is caused by the loss of the von Willebrand factor (vWF) high molecular weight multimers (HMWMs). We investigated whether the implantation of the left ventricular assist device HeartMate 3 (HM 3) is superior to the HeartWare ventricular assist device (HVAD) in preserving the multimeric structure of vWF. METHODS: In total, 70 patients with implanted HM 3 (n = 35) or HVAD (n = 35) were retrospectively investigated. HMWMs, intermediate molecular weight multimers and low molecular weight multimers were quantified by using a densitometric methodology. vWF antigen, vWF activity and vWF collagen-binding activity, as well as demographic and clinical data, were analysed. RESULTS: AvWS, which is characterized by a decrease in vWF HMWMs, was found in 97.1% of patients in the HM 3 group and 100% of patients in the HVAD group. Compared to normal pooled plasma, HM 3 induced a reduction in HMWMs (40.7 ± 8.2% vs 26.7 ± 7.5%, P < 0.01) and an increase in low molecular weight multimers (31.3 ± 11.8% vs 42.7 ± 9.8%, P < 0.01), whereas HVAD patients exhibited an increase in the percentage of intermediate molecular weight multimers (28.0 ± 5.0% vs 38.4 ± 7.7%, P < 0.01) in addition to a decrease in the percentage of HMWM (23.0 ± 11.0%, P < 0.01). A comparison of both left ventricular assist device types showed a difference in vWF multimeric structure (HMWMs: P < 0.01, intermediate molecular weight multimer: P = 0.05, low molecular weight multimer: P = 0.03). Furthermore, vWF activity was elevated in patients with an implanted HM 3 device (153.7 ± 54.4%) compared to those with an HVAD device (126.3 ± 39.7%, P = 0.02). CONCLUSIONS: Patients with an implanted HM 3 had more intact HMWMs and a higher vWF activity during device support. This may reduce the manifestation of AvWS in HM 3 patients and could thus lead to a lower bleeding complication rate.
引用
- Klaeske K, Dieterlen MT, Scholz U, et al. Acquired von Willebrand factor deficiency is reduced in HeartMate 3 patients†. Eur J Cardiothorac Surg. 2019. PMID: 30815698. doi:10.1093/ejcts/ezz045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。